Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research

Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.

Open to Debate: Is the FDA’s Caution Hazardous to your Health?

During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio had run a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to […]

World Congress: AI and Digital Twins to Drive the Next Generation Drug Discovery and Development

Watch Colin Hill’s talk at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session focused on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation was followed by a fireside chat with Julie Frearson, Chief Scientific Officer at Charles River Laboratories. This […]

Join Aitia at Charles River’s sixth Annual World Congress

We are excited to announce that Colin Hill will be speaking at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session will focus on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation will be followed by a fireside chat with Julie […]